XML 22 R12.htm IDEA: XBRL DOCUMENT
v3.25.1

Share-Based Payments | 9 Months Ended
--- | ---
Jan. 31, 2025
Share-Based Payment Arrangement [Abstract] |
Share-Based Payments | Share-Based Payments Stock-based compensation expense was recognized as follows (table in thousands):
| Three Months Ended January 31, |  | Nine Months Ended January 31, |
| 2025 |  | 2024 |  | 2025 |  | 2024 |
General and administrative | $ | 209 |  |  | $ | 272 |  |  | $ | 299 |  |  | $ | 487 |  |
Sales and marketing | 31 |  |  | 73 |  |  | 122 |  |  | 160 |  |
Research and development | 2 |  |  | 5 |  |  | 9 |  |  | 17 |  |
Cost of oncology revenue | 14 |  |  | 29 |  |  | 93 |  |  | 191 |  |
Total stock-based compensation expense | $ | 256 |  |  | $ | 379 |  |  | $ | 523 |  |  | $ | 855 |  |
The Company has in place a 2021 Equity Incentive Plan and 2010 Equity Incentive Plan (collectively, the "Plans"). In general, these Plans provide for stock-based compensation to the Company’s employees, directors and non-employees. The Plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards. 2021 Equity Incentive Plan As part of the 2021 Annual Shareholders Meeting, shareholders approved the adoption of the 2021 Equity Incentive Plan (“2021 Equity Plan”). The purpose of the 2021 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Incentive Stock Options; (iii) Restricted Stock Awards; and/or (iv) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2021 Equity Plan shall not exceed 2 million shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Company's Board of Directors. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of the common stock subject to the option or right at the date of grant. As of January 31, 2025, approximately 1.2 million shares were available for issue under this plan. Stock Option Grants Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2025 and 2024 were as follows:
| Three Months Ended January 31, |  | Nine Months Ended January 31, |
| 2025 |  | 2024 |  | 2025 |  | 2024 |
Expected term in years | 6 |  | 6 |  | 6 |  | 6 |
Risk-free interest rates | 4.09% - 4.34% |  | 4.49% |  | 3.58% - 4.48% |  | 3.95% - 4.49% |
Volatility | 54.54% - 56.37% |  | 63.41% |  | 54.54% - 62.72% |  | 62.83% - 63.41% |
Dividend yield | —% |  | —% |  | —% |  | —% |
The weighted average fair value of stock options granted during the three months ended January 31, 2025 and 2024 was $2.64 and $3.41, respectively. The weighted average fair value of stock options granted during the nine months ended January 31, 2025 and 2024 was $2.58 and $3.77, respectively. The Company’s stock options activity for the nine months ended January 31, 2025 was a s follows:
| Directors and Employees | Non- Employees |  |  | Total |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (Years) |  | Aggregate Intrinsic Value
Outstanding, April 30, 2024 | 1,883,166 |  | 36,331 |  |  |  | 1,919,497 |  |  | $ | 5.04 |  |  | 5.2 |  | $ | 2,172,000 |
Granted | 280,455 |  | — |  |  |  | 280,455 |  |  | 4.49 |  |  | 9.7 |  |
Exercised | (111,804) |  | — |  |  |  | (111,804) |  |  | 2.81 |  |  |  |  |
Forfeited | (213,625) |  | — |  |  |  | (213,625) |  |  | 6.50 |  |  |  |  |
Canceled | (3,750) |  | — |  |  |  | (3,750) |  |  | 5.99 |  |  |  |  |
Expired | (36,666) |  | — |  |  |  | (36,666) |  |  | 5.43 |  |  |  |  |
Outstanding, January 31, 2025 | 1,797,776 |  | 36,331 |  |  |  | 1,834,107 |  |  | $ | 4.91 |  |  | 5.1 |  | $ | 11,196,000 |
Vested and expected to vest as of January 31, 2025 | 1,797,776 |  | 36,331 |  |  |  | 1,834,107 |  |  | $ | 4.91 |  |  | 5.1 |  | $ | 11,196,000 |
Exercisable as of January 31, 2025 | 1,561,755 |  | 5,625 |  |  |  | 1,567,380 |  |  | $ | 4.92 |  |  | 4.4 |  | $ | 9,571,000 |
Share Repurchase Program On March 29, 2023, the Board of Directors approved a share repurchase program authorizing the Company to purchase up to an aggregate of $5.0 million of the Company’s common stock. The share repurchase program is designed in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The shares may be purchased from time to time in the open market, as permitted under applicable rules and regulations, at prevailing market prices. The timing and amount of repurchases will depend on market conditions, share price, applicable legal requirements and other factors. The program does not obligate the Company to acquire a minimum number of shares. As of January 31, 2025, the Company had purchased 120,333 shares of its common stock, at an average price of $5.73 per share, totaling approximately $708,000 and leaving an available balance of approximately $4.3 million authorized by the Board for use in the program as of that date. The last purchase was made during fiscal year 2024.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration